Clinically, it is generally not recommended that Febuxostat and Benzbromarone be taken at the same time, so it is not possible to assess how effective the two drugs are when taken together. Febuxostat is a xanthine oxidase inhibitor that reduces uric acid levels by inhibiting the production of uric acid, while Benzbromarone is a drug that strongly promotes the excretion of uric acid. Theoretically, these two drugs can be taken together, but clinically, it is generally not recommended to take Febuxostat and Benzbromarone at the same time because the combination of the two drugs may result in the superimposition of the adverse effects of the drugs. Both Febuxostat and Benzbromarone have some degree of hepatotoxicity, and their use together may increase the risk of hepatic impairment in patients, so it is not possible to assess how effective the two drugs are when taken together. Febuxostat and Benzbromarone should be used under the guidance of a physician. If the treatment effect of Febuxostat or Benzbromarone is unsatisfactory, the patient may increase the dosage of the drug or change the treatment plan after communicating with the physician, and it is recommended that the patient should go to endocrinology, rheumatology and immunology departments in regular hospitals to have a detailed consultation.